Deerborne Group to Attend ASCO 2026 and Highlight AI Platform COMPASS 360
The Deerborne Group announced in a press release that its senior leadership will attend the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which will take place from May 29 to June 2 in Chicago, Illinois.
At the event, the firm expects discussions to center on clinical utility, reimbursement strategy, regulatory expectations, and the integration of artificial intelligence with digital pathology and molecular diagnostics. The Deerborne Group will also present its COMPASS 360 platform, a strategic intelligence system powered by AI that combines market, clinical, competitive, reimbursement, and commercialization insights to support decision-making for diagnostics companies and investors.
The Deerborne Group provides consulting services to Fortune 500 companies, molecular diagnostics laboratories, biotechnology firms, and investment organizations, focusing on commercialization strategy, reimbursement, operational planning, and corporate growth in precision diagnostics.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Lunit and Discovery Life Sciences Partner on AI Tissue Analysis
Sopris Capital Acquires Blackford Analysis from Bayer
Basecamp Research Raises $140 Million for AI Designed Therapeutics
Veeva to Showcase Falcon and Vault AI at Boston Summit
Deep Longevity to Launch Accrua Telehealth Platform in US
Daily AI Brief: the AI news that matters, in your inbox.